Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose IVIG in Hospitalized COVID-19
NCT04432324Phase 2Completed
- Sponsor
- Grifols
- Start
- Jun 2020
- Primary completion
- Mar 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of intravenous immunoglobulin G in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Grifols. Primary endpoints: Percentage of Participants Dying or Requiring ICU Admission and Percentage of Participants Who are Dependent on High Flow Oxygen Devices or Invasive Mechanical Ventilation at Day 29. Started Jun 2020; status: completed.
02
Drugs
intravenous immunoglobulin G
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04432324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04432324.